VEGFA and neoplasm: Therapeutic combination of NK012 (5 or 30 mg/kg) with bevacizumab (5 mg/kg), an anti-VEGF humanized mAb, was more efficient than NK012 (5 or 30 mg/kg) at inhibiting tumor growth in nude mice subcutaneously implanted with human lung cancer (PC-14 or A549) xenografts [146].